Shares of 10x Genomics (NASDAQ:TXG) fell roughly 12% after ARK Invest disclosed the sale of more than 473,000 shares across its suite of flagship exchange-traded funds. The divestment from Cathie Wood’s firm represents a notable change in positioning for one of the most visible institutional holders of the genomics toolmaker.
Market participants interpreted the ARK transactions as a potential signal that other institutional investors might trim their exposure to the company, applying additional downward pressure on the stock. ARK Invest has been shifting capital away from companies that make genomic analysis instruments and toward firms focused on gene-editing platforms, a reallocation that was cited alongside the sell-off.
Investor sentiment was already fragile due to 10x Genomics’ guidance, which the company characterized as muted for revenue growth in 2026. That cautious outlook has weighed on expectations and appears to have amplified the market reaction when a large shareholder reduced its stake.
10x Genomics designs and sells instruments and software that enable researchers to analyze biological systems at single-cell resolution. The company’s tools are used by scientists working in oncology, immunology and neuroscience, among other research areas.
The combination of a major ETF manager reducing exposure, an ongoing sector rotation within biotech-related strategies, and tempered near-term growth guidance created a confluence of factors that pushed the stock lower. The sale by ARK Invest is both a discrete capital allocation decision and a market event that investors may view as indicative of changing convictions among large active managers.
Key points
- ARK Invest sold more than 473,000 shares of 10x Genomics across its flagship ETFs, coinciding with a roughly 12% drop in the stock price.
- ARK has been reallocating capital away from genomics toolmakers toward gene-editing platforms, reflecting a strategic shift within the firm.
- 10x Genomics’ instruments and software serve researchers in oncology, immunology and neuroscience, and the company issued muted revenue growth guidance for 2026 that has weighed on sentiment.
Risks and uncertainties
- Further selling by institutional investors could place additional downward pressure on the stock - this affects equity markets and investor demand within the genomics tools sector.
- Muted revenue growth guidance for 2026 creates uncertainty about near-term performance and investor expectations - this impacts valuation and capital allocation decisions among biotech-focused investors.
- Sector rotation from genomics toolmakers to gene-editing platforms may reduce demand momentum for certain equipment and software providers in the genomics tools market.
The market reaction to ARK Invest’s trades underscores how holdings by prominent active managers can influence sentiment, particularly for specialized technology and life sciences companies. 10x Genomics’ product set—focused on single-cell analysis—continues to serve key research areas, but near-term investor confidence will likely hinge on execution against the company’s revenue outlook.